An AI algorithm accurately evaluates pathologic response after neoadjuvant chemoimmunotherapy in patients with NSCLC, showing moderate concordance with expert pathologist consensus across cohorts.

Dr. Sonam Puri discusses the full update to the living guideline on stage IV NSCLC with driver alterations. She shares a new overarching recommendation on biomarking testing and explains the new ...

The National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) guidelines differ regarding recommended treatments for ...

Background: Biomarker testing is essential for guiding first-line treatment decisions in metastatic non–small cell lung cancer (mNSCLC). Despite guideline recommendations, real-world testing patterns ...

ALK: Anaplastic lymphoma kinase; BRAF: B-raf proto-oncogene, serine/threonine kinase; CDK: Cyclin-dependent kinase; EGFR: Epidermal growth factor receptor; JAK: Janus ...

Dr. Joshua Reuss is back on the podcast to discuss the full update to the living guideline on stage IV NSCLC without driver alterations. He discusses the new evidence and how this impacts the latest ...